Publications

Anti-CTGF Collagen/Gelatin HIF Anemia HIF Cytoprotection

Anti-CTGF

  • Anti-CTGF Antibody Therapy With FG-3019 Prevents Diabetes-induced Increase in Vascular Complications in Streptozotocin (STZ) Treated Rats

    Langsetmo, I. et al (2007) J Am Soc Nephrol.:16:199A

  • FG-3019, A Human Monoclonal Antibody to CTGF, With Gemcitabine/Erlotinib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
    Picozzi VJ et al. J Clin Oncol 30: 2012 (suppl 34; abstr 213)
  • Preclinical and Clinical Proof of Concept (POC) for Treatment of IPF with Anti-CTGF Antibody FG-3019
    Porter, S., et al. (2012) Presented at The 17th International Collquium on Lung & Airway Fibrosis: Poster 343
  • Phase 2 Trial of FG-3019, Anti-CTGF Monoclonal Antibody, In Idiopathic Pulmonary Fibrosis (IPF): Preliminary Safety and Efficacy Results
    Raghu G., et al. (2012) Eur Respir J 40: Suppl. 56, 511s
  • A Phase I Trial of the Monoclonal Antibody FG-3019 to Connective Tissue Growth Factor (CTGF) in Locally Advanced or Metastatic Pancreatic Cancer
    Heestand, G., et al. (2011) J Clin Oncol 29: (suppl 4; abstr 269)
  • The CTGF antibody FG-3019 blocks CTGF-stimulated migration of ovarian cancer cells
    Samimi, G. et al. Cancer Research July 12, 2011 71:509
  • Reversal of Established Fibrosis by Treatment with the Anti-CTGF Monoclonal Antibody FG-3019 in a Murine Model of Radiation-Induced Pulmonary Fibrosis
    Huber, P.E. et al. (2010) Am J Respir Crit Care Med 181:A1054
  • A Randomized, Double-blind, Placebo-controlled, Phase 1 Study of Safety, Pharmacokinetics and Pharmacodynamics of FG-3019 in Subjects with Type 1 or Type 2 Diabetes Mellitus and Diabetic Kidney Disease (DKD) on Background ACEi and/or ARB Therapy
    Singh, B., et al (2009) J Am Soc Nephrol. 20:423A
  • A Putative Role for Connective Tissue Growth Factor (CTGF) in Loss of Podocyte Slit Diaphragm Integrity and Actin Rearrangement
    Browne M., et al. (2008) J Am Soc Nephrol 19:138A
  • Connective Tissue Growth Factor (CCN2/CTGF) is Increased in High Peritoneal Solute Transport Rate in Peritoneal Dialysis Patients
    Mizutani M., et al. (2008) J Am Soc Nephrol 19:474A
  • CTGF Inhibits BMP-7 Signaling in Diabetic Nephropathy
    Nguyen T.Q., et al. (2008) J Am Soc Nephrol 19:2098-107
  • Modular Signaling Activities of the CTGF/CCN2 Domain Structure: Implications for Therapeutic Intervention
    O’Donovan H., et al. (2008) J Am Soc Nephrol 19:138A
  • BMP-Signaling and Podocyte Markers are Decreased in Human Diabetic Nephropathy in Association with CTGF Overexpression
    Turk T., et al. (2008) J Am Soc Nephrol 19:405A
  • A Targeted cDNA Microarray Identifies Cytoskeletal Regulatory Proteins as Transcriptional Targets of Connective Tissue Growth Factor (CTGF)/CCN2: Implications for Diabetic Nephropathy
    Browne M., et al. (2007) J Am Soc Nephrol 18:626A
  • Plasma Connective Tissue Growth Factor (CTGF; CCN-2) Predicts End-Stage Renal Disease and Mortality in Type 1 Diabetic Nephropathy
    Nguyen T.Q., et al. (2007) J Am Soc Nephrol 18:325A
  • Urinary Connective Tissue Growth Factor (CTGF) Excretion in Patients with Renal Allograft
    Peruzzi L., et al. (2007) J Am Soc Nephrol 18:244A
  • Dose-Escalation Phase I Study of FG-3019, Anti-CTGF Monoclonal Antibody, in Patients with Type 1/2 Diabetes Mellitus and Microalbuminuria
    Adler S.G., et al. (2006) J Am Soc Nephrol 17:157A
  • Connective Tissue Growth Factor-Specific Antibody Attenuates Tumor Growth, Metastasis, and Angiogenesis in an Orthotopic Mouse Model of Pancreatic Cancer
    Aikawa T., et al. (2006) Mol Cancer Ther 5(5):1108-16
  • Connective Tissue Growth Factor Specific mAb Therapy Inhibits Pancreatic Tumor Growth and Metastasis
    Dornhöfer N., et al. (2006) Cancer Res 1;66(11):5816-27
  • Anti-CTGF Human Antibody FG-3019 Prevents and Reverses Diabetes-Induced Cardiovascular Complications in Streptozotocin (STZ) Treated Rats
    Langsetmo I., et al (2006) Diabetes Vol. 55, Suppl.1;A122
  • FG-3019, a Neutralizing CTGF Monoclonal Antibody, Provides Renal, Metabolic and Cardio-Protective Effects in Obese Type 2 Diabetic Mice
    Usinger W., et al. (2005) J Am Soc Nephrol 16:197A
  • Long-Term Renal Effects of a Neutralizing Connective Tissue Growth Factor (CTGF)- Antibody in Obese Type 2 Diabetic Mice
    Flyvbjerg A., et al. (2004) J Am Soc Nephrol 15:261A
  • Connective Tissue Growth Factor (CTGF) Activates Nuclear Factor-kB (NF-kB) in Tubulo Epithelial Cells
    Lopez A.F., et al. (2004) J Am Soc Nephrol 15:678A
  • Safety and Tolerability of Human Monoclonal Antibody FG-3019, Anti-Connective Tissue Growth Factor, in Patients with Idiopathic Pulmonary Fibrosis
    Mageto Y., et al. (2004) CHEST 126:7735-a
  • Connective Tissue Growth Factor Differentially Mediates Transforming Growth Factorbeta1 Induced Fibrogenesis and Immunomodulation
    Qi W., et al. (2004) J Am Soc Nephrol 15:249A
  • Connective Tissue Growth Factor (CTGF) Expression Level in Podocytes Relates to Glomerular Basement Membrane (GBM) Thickening in STZ-Induced Diabetes Mellitus
    Roestenberg P., et al. (2004) J Am Soc Nephrol 15:265A
  • Connective Tissue Growth Factor (CTGF) Plasma Levels Correlate with Plasma Creatinine Levels in Patients with Type I Diabetes Mellitus (DM)
    Roestenberg P., et al. (2004) J Am Soc Nephrol 15:570A
  • Upregulation of Connective Tissue Growth Factor (CTGF) in Glomerular Epithelial Cells of Mice with STZ-Induced Diabetes Mellitus
    Roestenberg, P., et al. (2004) J Am Soc Nephrol 15:729A
  • Beneficial Effect of Dual Blockade of the Renin-Angiotensin System (RAS) on Urinary Connective Tissue Growth Factor (CTGF) in Type 2 Diabetic Patients with Nephropathy
    van Nieuwenhoven F.A., et al. (2004) J Am Soc Nephrol 15:571A
  • Amelioration of Diabetic Nephropathy (DN) Induced by Renal Ischemia-Reperfusion (IR) in Rats with Diabetes Mellitus (DM) by Treatment with FG-3019, a Monoclonal Antibody Against Connective Tissue Growth Factor (CTGF)
    Wang Q., et al. (2004) J Am Soc Nephrol 15:731A
  • Human Urinary CTGF (CCN2) as a Predictor of Progression of Chronic Renal Diseases
    Ito Y., et al. (2003) J Am Soc Nephrol 65:153A
  • Connective Tissue Growth Factor (CTGF): A Biomarker of Chronic Allograft Nephropathy (CAN)
    Mannon R., et al. (2003) J Am Soc Nephrol 14:12A
  • Control of CTGF Expression by Fibroblasts: Role of IFNgamma, TNF-alpha and the Proteasome

    Leask A., et al., (2000) 6th International Workshop on Scleroderma Research

  • Back to Top

Collagen/Gelatin

  • Expression and Characterization of Recombinant Human Gelatin Fragments

    Olsen D., et al. (2000) American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition

  • Back to Top

HIF Anemia

  • Anemia Correction with Roxadustat Lowers Hepcidin in Chronic Kidney Disease (CKD) Patients

    Szczech L., et al (2015) J Am Soc Nephrol 26:237A

  • Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
    Besarab A., et al (2015) Nephrol Dial Transplant 30:8
  • Anemia Correction with Roxadustat Improves Health Related Quality of Life (HRQOL) in Chronic Kidney Disease (CKD) Patients
    Szczech L., et al (2015) J Am Soc Nephrol 26:11A
  • Anemia Correction with Roxadustat Lowers Cholesterol in Chronic Kidney Disease (CKD) Patients
    Szczech L., et al (2015) J Am Soc Nephrol 26:237A
  • Anemia Correction with Roxadustat Increases Soluble Transferrin Receptor (sTfR) in Chronic Kidney Disease (CKD) Patients
    Szczech L., et al (2015) J Am Soc Nephrol 26:237A
  • Impact of Iron Regimen on Iron Indices and Hepcidin during Roxadustat Anemia Correction in Incident Dialysis Patients
    Besarab A., et al. (2014) J Am Soc Nephrol 25:304A
  • Hypoxia Inducing Factor Prolyl Hydroxylase Inhibitor FG-4592 Corrects Anemia In Peritoneal Dialysis
    Besarab A., et al. (2013) J Am Soc Nephrol 24:91A
  • A Randomized, Double-Blind, Placebo Controlled Trial of FG-4592 for Correction of Anemia in Subjects with Chronic Kidney Disease in China
    Qian J., et al. (2013) J Am Soc Nephrol FR-OR011
  • FG-4592, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase-Inhibitor, Corrects Anemia Without Iron Supplementation in Incident Dialysis Patients
    Besarab A, et al. (2012) J Am Soc Nephrol 23:428A
  • FG-4592, a Novel Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), Maintains Hemoglobin Levels and Lowers Cholesterol in Hemodialysis (HD) Patients: Phase 2 Comparison with Epoetin Alfa
    Provenzano, et al. (2012) J Am Soc Nephrol 23:428A
  • FG-4592 Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Corrects Anemia in Nondialysis CKD Patients without IV Iron
    Besarab A, et al. (2011) J Am Soc Nephrol 22:196A
  • Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
    Bernhardt W, et al. (2010) J Am Soc Nephrol 21: 2151–2156
  • FG-4592, A Novel Oral HIF Prolyl Hydroxylase Inhibitor, Elevates Hemoglobin in Anemic Stage 3/4 CKD Patients
    Besarab A., et al (2010) J Am Soc Nephrol 21:201:95A
  • Induction of Erythropoiesis in Rodents by Novel and Distinct Families of Orally Active HIF Prolyl Hydroxylase Inhibitors
    Klaus S., et al. (2008) Keystone Symposium Molecular, Cellular, Physiological and Pathogenic Responses of Hypoxia (Abstract 301)
  • Correction of Anemia without Exacerbation of Hypertension in a Rat Model of Chronic Kidney Disease: Comparison of FG-2216 to Recombinant Erythropoietin
    Guo G., et al. (2008) J Am Soc Nephrol 19:654A
  • Beneficial Pharmacodynamic Effects Resulting from 'Complete Erythropoiesis' Induced by Novel HIF Prolyl Hydroxylase Inhibitors FG-2216 and FG-4592
    Klaus S., et al. (2008) J Am Soc Nephrol 19:524A
  • FG-2216, A Novel Oral HIF-PHI, Stimulates Erythropoiesis and Increases Hemoglobin Concentration in Patients With Non-Dialysis CKD
    Provenzano R., et al. (2008) American Journal of Kidney Diseases; April;Vol. 51, Issue 4, Page B80
  • HIF Prolyl Hydroxylase Inhibitors Increase Erythropoiesis Without Promotion of Tumor Progression in the Presence or Absence of Concomitant Chemotherapy
    Seeley T., et al. (2008) Keystone Symposium Molecular, Cellular, Physiological and Pathogenic Responses of Hypoxia (Abstract 364)
  • The Prolylhydroxylase Inhibitor FG2216 Stimulates EPO Production in Nephric and Anephric Dialysis Patients - Evidence for an Underutilized Production Capacity in Liver and Kidneys
    Bernhardt W.M., et al. (2007) J Am Soc Nephrol 18:515A
  • Preliminary Results from a Randomized, Single-Blind, Placebo-Controlled Trial of FG-4592, a Novel Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor, in Subjects with CKD Anemia
    Frohna P.A., et al. (2007) J Am Soc Nephrol 18:763
  • HIF-PH Inhibitor, FG-4592, Treats Anemia and Prevents Elevation of SBP in Uremic Rats
    Guo G, et al. (2007) J Am Soc Nephrol 18:154A
  • HIF-Prolyl Hydroxylase Inhibition Results in Endogenous Erythropoietin Induction, Erythrocytosis, and Modest Fetal Hemoglobin Expression in Rhesus Macaques
    Hsieh M., et al. (2007) Blood Sep 15;110(6):2140-7
  • HIF Prolyl Hydroxylase Inhibitors Potentiate EPO Signaling, Enhance Erythropoiesis and Overcome Inhibitory Effects of Pro-Inflammatory Cytokines in Anemia of Chronic Disease
    Sirenko O., et al. (2006) Keystone Symposium Hypoxia and Development, Physiology and Disease (Abstract 332)
  • FG-2216 Increases Hemoglobin Concentration in Anemic Patients with Chronic Kidney Disease
    Guenzler V., et al. (2005) J Am Soc Nephrol 16:758A
  • Induction of Erythropoiesis and Iron Utilization by the HIF Prolyl Hydroxylase Inhibitor FG-4592
    Klaus S., et al. (2005) J Am Soc Nephrol 16:49A
  • FG-2216 Corrects Anemia and Improves Iron Utilization in a Rat Model of Anemia of Chronic Disease: Comparison to Darbepoetin
    Langsetmo I., et al. (2005) J Am Soc Nephrol 16:481A
  • Novel and Beneficial Pharmacodynamic Properties of Endogenous EPO and 'Complete Erythropoiesis' Induced by Selective HIF Prolyl Hydroxylase Inhibitors
    Liu D., et al. (2005) J Am Soc Nephrol 16:761A
  • FG-2216: Tumor Progression Studies and Correction of Anemia of Chronic Disease in Xenograft Models
    Seeley T, et al. (2005) J Am Soc Nephrol 16:481A
  • Induction of Renal and Extra-Renal Erythropoietin Production by Orally Bioavailable HIF Prolyl Hydroxylase Inhibitors
    Wang Q., et al. (2005) J Am Soc Nephrol 16:483A
  • Novel Prolyl Hydroxylase Inhibitors Overcome Inflammatory Cytokine-Mediated Suppression of EPO Secretion
    Klaus S., et al. (2004) J Am Soc Nephrol 15:449A
  • Effect of FG-2216 on Anemia and Iron Transport in a Rat Model of Anemia of Chronic Disease
    Langsetmo I., et al. (2004) J Am Soc Nephrol 15:548A
  • Upregulation of Endogenous EPO in Healthy Subjects by Inhibition of HIF-PH
    Urquilla P., et al. (2004) J Am Soc Nephrol 15:546A
  • Stimulation of Erythropoiesis and Treatment of Anemia in Rodents by Oral Administration of FG-2216, a Novel HIF-Prolyl Hydroxylase Inhibitor
    Wang Q., et al. (2004) J Am Soc Nephrol 15:773A
  • Back to Top

HIF Cytoprotection

  • Donor Pre-treatment with a HIF Prolyl Hydroxylase Inhibitor Improves Function and Increases Long-Term Graft Survival in an Allogenic Rat Transplant Model
    Bernhardt W., et al. (2007) J Am Soc Nephrol 18:64A
  • Preconditional Activation of HIF Ameliorates Ischemic Acute Renal Failure
    Bernhardt W., et al. (2005) J Am Soc Nephrol 16:195A
  • Inhibition of Collagen Synthesis with Prolyl 4-Hydroxylase Inhibitor Improves Left Ventricular Function and Alters the Pattern of Left Ventricular Dilatation After Myocardial Infarction
    Nwogu J.I., et al. (2001) Circulation Oct 30;104(18):2216-21
  • Back to Top